The World Health Organization (WHO) has announced that, at present, it will not proceed with its proposal to use biological qualifiers (BQ) to assign international nonproprietary names to biosimilars.
The World Health Organization (WHO) has announced that, at present, it will not proceed with its proposal to use biological qualifiers (BQ) to assign international nonproprietary names to biosimilars.
The announcement was part of an October 2017 WHO publication, “Report on the Expert Consultation on Improving Access to and Use of Similar Biotherapeutic Products,” which covered a May 2017 meeting held in Geneva, Switzerland, to address concerns about improving access to, education about, and the use of biosimilars. The expert consultation was convened by WHO to gather stakeholder opinions regarding policy initiatives, technical requirements for manufacturing, regulatory support tools such as potential BQs, and building trust in biosimilars.
The October report noted that no consensus was reached during the meeting on whether WHO should move forward with the BQ; the system would have been similar to the system used by the FDA, which assigns biosimilars nonproprietary names that have non-meaningful 4-letter suffixes that distinguish them from originator or other biosimilar products. The Biosimilars Council, a trade group for biosimilar manufacturers, praised WHO’s announcement on Twitter, saying that then use of an added identifier for biosimilar drugs would act as an additional barrier to both patient access and cost savings.
At the May meeting, WHO decided to proceed with a separate project, a pilot concerning the prequalification (PQ) of 2 biosimilar cancer therapeutics—rituximab and trastuzumab. The aim of the project is to use 2 assessment pathways for biosimilar applicants: the first based on biosimilars with approvals from a Stringent Regulatory Authority (SRA), and the other a pathway for applicants approved by other national regulatory authorities. WHO will provide clear guidance to manufacturers wishing to apply for the pilot project.
The May meeting also addressed interchangeability of biosimilars with originator biologics, the complexities and diversities of nomenclature, and the principle of biosimilarity. Lessons learned and recent experiences with biosimilars were presented by representatives from Australia, Norway, India, and Brazil. The meeting also included presenters from the pharmaceutical industry, patient groups, and professional societies, who offered a wide range of perspectives on recurrent themes:
In addition to the announcement concerning the BQ and the pilot programs for rituximab and trastuzumab biosimilars, WHO concluded that the organization will review and provide clarification on the organization’s 2009 biosimilar guidelines to reflect technological and analytical advances and experience gained in the following years.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.